Judith Balmañà - Concepedia

Author

Judith Balmañà

Vall d'Hebron Hospital Universitari ORCID

Also Known As

Andrew Berchuck, Angel Izquierdo, Ava Kwong, Balmaña, Judith, Banu K. Arun, Bottomley, A, Bottomley, A., C Sessa, Conxi Lázaro, Hoadley, Katherine A.

600

Publications

18.8K

Citations

H-Index

100

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Vall d'Hebron Institute of Oncology Dana-Farber Cancer Institute Universitat Autònoma de Barcelona Institut Català d'Oncologia

About

Judith Balmañà is an author at Vall d'Hebron Hospital Universitari specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	73	6.4K
2	Public Health	15	17	1.5K
3	Health Sciences	6	6	282
4	Engineering	3	3	119
5	Natural Sciences	3	3	74

Judith Balmañà

150

Publications

14.1K

Citations

H-Index

Page 1

	Year	Citations
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler, Journal of Clinical Oncology	2014	1.7K
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein, Annals of Oncology Esmo Consensus GuidelinesPersonalized ApproachGastrointestinal OncologyColorectal SurgeryMedicine	2012	1.5K
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer Ashish Juvekar, Laura N. Burga, Hai Hu, Cancer Discovery	2012	475
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez, Annals of Oncology	2018	410
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families Xin Yang, Goska Leslie, Alicja Doroszuk, Journal of Clinical Oncology	2019	393
Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening Shani Paluch–Shimon, Fátima Cardoso, Cristiana Sessa, Annals of Oncology Breast OncologyCancer ScreeningMedicineBrca Mutation CarriersGynecology	2016	392
Mutational spectrum in a worldwide study of 29,700 families with<i>BRCA1</i>or<i>BRCA2</i>mutations Timothy R. Rebbeck, Tara M. Friebel, Eitan Friedman, Human Mutation Brca1 MutationsGenetic TestingGeneticsGenetic EpidemiologyMolecular Genetics	2018	298
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy Susan M. Domchek, Carol Aghajanian, Ronnie Shapira‐Frommer, Gynecologic Oncology Endocrine-related CancerMedicineCancer ManagementGynecologyCancer Treatment	2015	297
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg, Cell Reports	2016	279
A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, EMBO Molecular Medicine	2018	263

Page 1